摘要
目的观察胰腺癌患者血浆中组织因子途径抑制物-2(TFPI-2)基因启动子区甲基化状态,并探讨其临床意义。方法采用甲基化特异性聚合酶链反应(MSP)检测62例胰腺癌患者(观察组)及30例胆胰非肿瘤疾病患者(对照组)血浆中的TFPI-2基因甲基化状态。结果观察组血浆TFPI-2基因甲基化阳性率为66.13%(41/62),明显高于正常对照组的3.33%(1/30),P<0.01。血浆TFPI-2基因甲基化与胰腺癌的临床分期、组织分化程度有关(P均<0.05)。结论胰腺癌患者血浆中TFPI-2基因出现异常甲基化;血浆TFPI-2基因甲基化检测可能有助于胰腺癌的早期诊断。
Objective To investigate the tissue factor pathway inhibitor （TFPI）-2 gene promoter aberrant methylation in the plasma of patients with pancreatic cancer and analyse its possible clinical signifiance. Methods Methylation-specific PCR was used to detect promoter methylation of the TFPI-2 gene in the plasma from 62 patients with pancreatic cancer and 30 nontumorous patients. Results Promoter methylation of TFPI-2 was found in 66.13 % （41/62） of pancreatic cancer patients and 3.33 % （1/30） of control samples （P 〈 0.01 ）. The positive rate of TFPI-2 methylation was related to clinical stage, tissue differentiation of carcinoma （P 〈 0.05 ）. Conclusion There is aberrant methylation of TFPI-2 gene in pancreatic cancer patients plasma, which may be helpful for early diagnosis of pancreatic cancer.
出处
《山东医药》
CAS
北大核心
2011年第34期20-21,共2页
Shandong Medical Journal
